SRI International to Present SERM Case Study at the American Association for Cancer Research Annual Meeting
Menlo Park, CA.,– April 9, 2008– SRI International, an independent, nonprofit scientific research institute, announced today that a case study on successfully converting an effective molecule into an approved drug will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2008, to be held April 12-16 in San Diego, California.
Lidia Sambucetti, Ph.D., director of cancer drug discovery in SRI's Biosciences Division, will be one of four lecturers in a 3:15 pm – 5:15 pm education session on Saturday, April 12 titled, "From Chemistry to the Clinic: Pathways for Drug Discovery and Development." Dr. Sambucetti will discuss the development process needed to produce the chemistry, manufacturing and controls (CMC) package suitable for clinical filing and subsequent approval with the FDA and present a case study describing the development of novel tissue-selective, estrogen receptor modulators (SERMs).
"SRI does a tremendous amount of work translating ideas into promising new therapies. We know that the development process to produce a compound suitable for clinical filing and eventual approval is detailed and complex," said Dr. Sambucetti. "For this reason, it is imperative to have a focused multidisciplinary discovery and development team."
Dr. Sambucetti's case studies will describe how challenges were successfully met in the development of a new steroidal estrogen receptor antagonist (SR16234/TAS-108), currently in clinical trials, and demonstrate the innovation that led to other novel anti-cancer agents (SR16157, SR16388) with unique profiles and mechanisms-of-action.
Other lecturers joining Dr. Sambucetti on the panel include William Bauta of Genzyme Corporation, James Porter of Infinity Pharmaceuticals and Anthony Haight of Abbott Laboratories.
About SRI's Biosciences Division
SRI International’s Biosciences Division teams with pharmaceutical and biotechnology companies, academia, foundations, and government agencies to solve important problems in global health. SRI Biosciences conducts basic research, drug discovery, and drug development, including contract research. SRI has all of the resources necessary to take R&D programs from "idea to IND"™—from initial discovery to investigational new drug applications to start human clinical trials—and specializes in cancer, immunology and inflammation, infectious disease, and neuroscience research. To date, SRI has helped advance more than 100 drugs into clinical trials, including a number of its own discoveries, several of which have reached the market. SRI is also working at the nexus of science and technology to create new technology platforms for the next generation of drug discovery and development in areas such as diagnostics, drug delivery, medical devices, and systems biology.
About SRI International
Silicon Valley-based SRI International is one of the world's leading independent research and technology development organizations. Founded as Stanford Research Institute in 1946, SRI has been meeting the strategic needs of clients and partners for more than 60 years. The nonprofit research institute performs client-sponsored research and development for government agencies, businesses, and foundations. In addition to conducting contract R&D, SRI licenses its technologies, forms strategic partnerships, and creates spin-off companies.
